| Abstrakt: |
Dr. Karl Petri of the University Hospital Wurzburg aims to address the challenges of CAR-T cell therapy, which is highly effective in treating selected blood cancers but has limitations in treating solid tumors and producing durable remissions. He plans to use an advanced CRISPR method called CRISPR Prime Editing to increase the efficiency of cancer-directed immunotherapies. The project, called Prime-CAR Inspection, also aims to standardize the safety validation of new gene-editing techniques to provide more effective CAR-T cell products for patients with multiple myeloma and other cancers. The research takes place in a unique research environment at the University of Wurzburg, which has expertise in CAR-T cell therapy and CRISPR research. [Extracted from the article] |
